Mutations in gliclazide-associated genes may predict poor bladder cancer prognosis

Weiheng Wen1, Jinru Gong2, Peili Wu1, Min Zhao1, Ming Wang3, Hong Chen1 and Jia Sun1

1 Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou, China
2 State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, China
3 Department of Traditional Chinese Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China

Keywords
bioinformatics; bladder cancer; diabetes; gliclazide

Correspondence
J. Sun and H. Chen, Department of Endocrinology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China and M. Wang, Department of Traditional Chinese Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China
Fax: +86 206 1643 195
Tel: +86 206 1643 195
E-mails: sunjia@smu.edu.cn (JS), chenhong123@smu.edu.cn (HC), wming1999@163.com (MW)

Weiheng Wen, Jinru Gong and Peili Wu contributed equally to this work

(Received 15 August 2018, revised 22 November 2018, accepted 13 December 2018)

doi:10.1002/2211-5463.12583

In recent years, an increasing number of patients have had diabetes and cancer simultaneously; thus, it is crucial for physicians to select hypoglycemic drugs with the lowest risk of inducing cancer. Gliclazide is a widely used sulfonylurea hypoglycemic drug, but its cancer risk remains controversial. Here, we explored the primary targets of gliclazide and its associated genes by querying an available database to construct a biological network. By using DrugBank and STRING, we found two primary targets of gliclazide and 50 gliclazide-associated genes, which were then enrolled for Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis using WebGestalt. From this analysis, we obtained the top 15 KEGG pathways. Accurate analysis of these KEGG pathways revealed that two pathways, one linked to bladder cancer and the other linked to the phosphoinositide 3-kinase–AKT signaling pathway, are functionally associated with gliclazide, and from these we identified four overlapping genes. Finally, genomic analysis using cBioPortal showed that genomic alterations of these four overlapping genes predict poor prognosis for patients with bladder cancer. In conclusion, gliclazide should be used with caution as a hypoglycemic drug for diabetic patients with cancer, especially bladder cancer. In addition, this study provides a functional network analysis to flexibly explore drug interaction systems and estimate their safety.

The prevalence of diabetes and cancer is increasing rapidly worldwide. In 2015, more than 415 million people were identified as diabetes patients, and 90% of these were classified as having type 2 diabetes (T2DM) [1]. By 2040, this number is projected to be 642 million [1]. It is estimated that more than 80% of diabetes patients live in low-income and middle-income countries, but the prevalence of diabetes in every country has been increasing since 1980 [2]. Meanwhile, the global cancer incidence predicted by the World Health Organization will increase to 22 million in 2032, and more than 60% of these cases will occur in Africa, Asia, and Central and South America [3]. Diabetes and cancer are closely interrelated in epidemiology and biology. Both of these two disorders share many of the same risk factors, including obesity, aging, physical inactivity, and irregular diet [3]. As a result, an increasing number of patients are experiencing both diabetes and cancer.

Gliclazide, a second-generation oral sulfonylurea agent, has a strong hypoglycemic effect [4]. It can be administered in lower doses and used on a once-daily basis. Gliclazide increases peripheral glucose utilization

Abbreviations
ABCC8, ATP-binding cassette transporter subfamily C member 8; KEGG, Kyoto Encyclopedia of Genes and Genomes; PI3K, phosphoinositide 3-kinase; T2DM, type 2 diabetes; VEGFA, vascular endothelial growth factor A.
through activation of hepatic gluconeogenesis and possibly by increasing insulin receptors and sensitivity in specific tissues [5]. After binding of gliclazide to a specific sulfonlurea receptor on the β-cell plasma membrane, it subsequently activates an effector system of insulin secretion. Gliclazide has also been found to have an extrapancreatic effect and thus enhances the sensitivity of peripheral tissues to insulin, which may be the result of augmented biological effects of post-insulin receptors [5]. The new Dutch guideline for T2DM has taken gliclazide as the preferred second-line drug. Compared with other sulfonylureas, gliclazide has a low risk of hypoglycemic events, which may be explained by the pattern of insulin secretion. The higher reversibility of gliclazide binding to a specific sulfonlurea receptor on β cells resulted in a lesser pancreatic overstimulation, which is the result of fewer hypoglycemic events [6,7].

Recently, it has been suggested that the use of anti-diabetic drugs may affect the risk of cancers in T2DM. The use of metformin, for example, has been reported to reduce the risk of cancer [8], while the use of sulfonlurea on cancer risk is still under debate [9–11]. In a population-based cohort study, increased cancer-related mortality was found in patients who used sulfonlurea rather than metformin [12]. Another observational cohort study containing 568 patients with T2DM showed that glibenclamide users experienced higher mortality for malignancies than gliclazide users [13]. Some studies have indicated that different types of sulfonlurea exert different effects on tumors, and gliclazide tends to have beneficial effects on diabetes patients with tumors [10,13]. However, Piccinni and colleagues found that use of gliclazide in bladder cancer led to more adverse events [11]. Apart from the inadequate adjustment for confounders, such as complications caused by diabetes and cancers, different effects of gliclazide on specific cancers might contribute to these inconsistent findings, although the relevant research on this topic is limited.

With the rapid development of global genomics research, such as microarray analysis, proteomics assays, and high-throughput screening research, integration of these available resources has become a flexible yet effective method to determine the relationship between drugs and diseases. In this study, we used DrugBank to study gliclazide and its drug-target information to further explore gliclazide’s underlying pharmacological effects. Based on the direct targets found by DrugBank and associated genes generated by STRING, we further performed pathway enrichment analysis through WebGestalt; the bladder cancer pathway and phosphoinositide 3-kinase (PI3K)–AKT pathway were screened, and then seven overlapping genes were identified to further analyze their genomic alterations through the eBioPortal database. Taken together, the aim of our research based on these systematic network studies was to explore the safety profile of gliclazide on patients with specific tumors, such as bladder cancer, which reminds us that more in-depth studies involving the effects of gliclazide on different types of tumors should be conducted.

## Results

### Characterization of bioactivities of gliclazide by DrugBank and visualization of gliclazide linkage network by STRING

In biosystems, interactions between chemical substances (including drugs or agents), proteins, and gene levels bring a range of biological effects that influence energy homeostasis. To reduce the complexity of analysis, multiple interactions can be visualized as a network. For example, individual nodes can represent biological entities, and the connections between nodes can represent different types of interactions. We first queried DrugBank using gliclazide as an input, which displayed an output of DB01120, categorizing gliclazide as a blood glucose lowering agent, cytochrome P-450 enzyme inhibitor, sulfonylurea compound, and urea (Table 1). Among these, the main use of gliclazide is to improve glucose metabolism in conjunction with diet and exercise. Table 2 displays two primary direct targets of gliclazide, ATP-binding cassette transporter subfamily C member 8 (ABCC8) and vascular endothelial growth factor A (VEGFA). To expand our study and analysis, we used STRING to generate a total of 50 gliclazide-related target proteins (Table S1). This dataset combined with its two primary

| DB_ID  | Name     | Group | Category                        | Indication                                                      |
|--------|----------|-------|---------------------------------|-----------------------------------------------------------------|
| DB01120| Gliclazide| Approved | Blood glucose lowering agents | For the treatment of non-insulin-dependent diabetes mellitus in conjunction with diet and exercise |

|                        | Cytochrome P-450 enzyme inhibitors | Sulfonylurea compounds |
|------------------------|-----------------------------------|------------------------|
| Urea                   |                                    |                        |
targets was then collectively integrated to build a biological function network using CYTOSCAPE 3.6, thereby displaying a gliclazide network and the visualization of gliclazide-related protein interactions. The two primary direct targets and their secondary gliclazide-associated proteins, ABCC8 (five protein targets) and VEGFA (47 protein targets), are shown in Fig.1. Two genes, HSP90AA1 and ALB, were identified as the common genes linked to both VEGFA and ABCC8. It has been reported that HSP90AA1 is critical to the survival and proliferation of cancer [14]. Additionally, the serum level of ALB protein can be used to predict the prognosis of cancer patients [15,16].

**Analysis of functional features related to gliclazide-mediated changes in gene set by WebGestalt**

To explore the functional attributes of gliclazide-mediated gene sets, two direct targets found by DrugBank and 50 gliclazide-related genes generated by STRING were used for KEGG pathway analysis using WebGestalt. The top 15 enrichment pathways associated with gliclazide include epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor resistance (15 genes), Rap1 signaling pathway (23 genes), hypoxia inducible factor-1 (HIF-1) signaling pathway (17 genes), PI3K–Akt signaling pathway (23 genes), focal adhesion (22 genes), pathways in cancer (28 genes), proteoglycans in cancer (22 genes), renal cell carcinoma (14 genes), Ras signaling pathway (19 genes), prostate cancer (13 genes), melanoma (11 genes), endocrine resistance (11 genes), bladder cancer (eight genes), cytokine–cytokine receptor interaction (14 genes), and breast cancer (11 genes). All identified biologically effective pathways were statistically significant and thereby warranted further exploration. Broad grouping of the biological function investigation showed that gliclazide-related genes are closely associated with cancer and its related signal pathway cascades, including (a) regulation of cancer cell proliferation via the tyrosine kinase inhibitor resistance pathway, (b) regulation of tumor growth, invasion, metastasis, and treatment resistance via the HIF-1 signaling pathway, and (c) regulation of cancer signaling cascades via the PI3K–Akt pathway.

The role of gliclazide in cancer remains controversial, and there is limited research on the effects of gliclazide on site-specific cancer types. Therefore, more studies should be conducted to evaluate the safety profile of gliclazide on different types of cancers. It has been reported that use of gliclazide in bladder cancer patients caused more adverse events [11], and thus, the bladder cancer pathway was screened for further

### Table 2. Identification of direct targets of gliclazide using DrugBank.

| DB_ID  | Name   | Target ID | Actions | Organism   |
|--------|--------|-----------|---------|------------|
| DB01120 | Gliclazide | ABCC8 Q09428 | Binder  | Human      |
| DB01120 | Gliclazide | VEGFA P15692 | Other/unknown | Human      |

![Fig. 1. Drug–target interactome of gliclazide. Drug: gliclazide (in yellow); primary direct protein targets: VEGFA and ABCC8 (in red); secondary gliclazide-associated protein (in purple).](image)
analysis. Additionally, the Cancer Genome Atlas Research Network found that three major signaling pathways were dysregulated frequently in bladder cancer, namely cell cycle regulation, chromatin remodeling, and PI3K signaling [17]. It is generally believed that the PI3K pathway plays an important part in the development of bladder cancer [18,19]. Also, KEGG enrichment analysis showed that the PI3K–Akt pathway is tightly related to the gliclazide-associated network. It seems that gliclazide is more likely to affect bladder cancer development through this pathway. Accordingly, we select the intersection of two gene sets, namely the bladder cancer and PI3K–Akt pathways, which then generates four common genes, EGF, EGFR, THBS1, and VEGFA (EntrezGene ID: 1950, 1956, 7057, 7422). Notably, the identified VEGFA gene is the direct target of gliclazide. VEGFA is a member of the growth factor family and mediates angiogenesis [20]. Several studies have also reported that VEGFA can activate bladder cancer progression [21,22].

Mining genomic alterations related to gliclazide-associated genes in bladder cancer using cBioPortal

To further explore the link between gliclazide-associated genes and the bladder pathway, cBioPortal was used to uncover genomic alterations of gliclazide-associated genes in bladder cancer. A summary of seven bladder cancer studies was included in cBioPortal [17,23–27]. One study was excluded for being accepted provisionally. In order to comprehensively and accurately evaluate the genomic alterations in bladder cancer, a gene set containing four identified genes (EGF, EGFR, THBS1, and VEGFA) performed as in the study of The Cancer Genome Atlas Research Network [17], whose genomic profiles included additional mRNA and protein expression levels compared to the other six studies. The results showed that 51 cases (38.93%) have alterations in all four genes (Fig. 2A); the frequency of alteration of four identified genes is shown in Fig. 2B. For EGFR (20%), most alterations were mRNA upregulation and amplification, with a few cases of missense mutation and protein upregulation. For EGF (11%), the majority of alterations were mRNA upregulation, with a small fraction of amplification and missense mutation. Gene changes associated with VEGFA were amplification and mRNA upregulation, and changes associated with THBS1 were amplification, mRNA upregulation, and deep deletion.

cBioPortal also can be used to analyze the interactive analysis and construct networks which are altered in bladder cancer. We first built a network including all neighbors of four identified genes, EGF, EGFR,
THBS1, and VEGFA (Fig. 3). Next, we took the genomic alteration frequency within the screened bladder cancer study as a filter such that only the genes with high alteration frequency were displayed, thereby reducing the complexity of the analysis. First, the four selected genes were identified to be associated with PIK3CA using a filter of 30.5% alteration. Comparatively, five genes, including PIP5K1A, were displayed using a filter of 29.0% alteration. A cluster of eight genes, including PIK3CA, PIP5K1A, TRIO, and F5, were shown after the filter was decreased to 27.4%, while 10 genes, including PIK3CA, PIP5K1A, TRIO, F5, PITPNA, and BRK1, were demonstrated with a filter of 25.9%. The integrated and pruned networks showed the underlying interactions and the variability of differences between glisiclide-associated genes and the bladder cancer samples in the study of [17] (Fig. 3).

To further explore the association between genomic alterations of glisiclide-associated genes and the survival of patients with bladder cancer, the four identified genes (EGF, EGFR, THBS1, and VEGFA) were used to perform a survival analysis as in the study of The Cancer Genome Atlas Research Network [17]. The result showed that patients with alterations in four identified genes had a lower overall survival rate ($P = 0.0289$) (Fig. 4).

**Discussion**

Type 2 diabetes is a growing global health problem, which results in serious acute and chronic complications that affect the quality of people’s lives. Current epidemiological evidence indicates that diabetes increases the risk of cancers, and the possible biological mechanisms may be associated with hyperinsulinemia, hyperglycemia, and chronic inflammation [28]. As such, an increasing number of patients have diabetes and cancer at the same time, making it essential for patients to use hypoglycemic drugs that have no effect on cancer treatment. To our knowledge, the impact of sulfonylurea drugs on cancer has not yet been determined, but some studies have suggested that this result may be caused by different effects of different sulfonylurea drugs on cancer, such as the benefit of the use of glisiclide for cancer [10,29]. However, glisiclide also has been reported to cause more side effects in bladder cancer patients [11]. Apart from not excluding complex confounding factors, limited research on glisiclide has
been performed in specific cancer types contributing to these inconsistent results. Therefore, a new analytical technique and platforms are required to assess the effect of gliclazide on specific types of cancer.

In this study, we used a set of web-based tools to analyze the functional network of gliclazide, which also helped to eliminate the interference of confounding factors in clinical research. We explored the molecular action of gliclazide by querying cancer genomics data in three open platforms, DrugBank, STRING, and cBioPortal. This flow of work contains two simple procedures: (a) exploring the direct targets of gliclazide and functional network with gliclazide-associated protein using DrugBank and STRING, and (b) identifying whether genomic alterations of gliclazide-associated genes exist in the sample in cancer genomic projects using cBioPortal. This study helped us to interactively explore the effective targets of gliclazide, further explore the biological effect pathways based on the target and gliclazide-associated genes, and finally connect to the clinical results formulated by mining multiple web-based databases. Also, this approach, with significant biological rationality, can not only effectively integrate and use existing resources, but also reduce unnecessary experiments and give better direction for scientific research.

In this study, we constructed a functional network to illustrate the connectivity between gliclazide and cancer using open integrated databases. Analysis of gliclazide through these accessible platforms identified two primary target proteins (ABCC8 and VEGFA), another 50 gliclazide-related proteins and the enriched KEGG pathway closely associated with gliclazide (Fig. 1). In accordance with the known functional features with gliclazide-related genes and KEGG pathway analysis, we found that 28 genes were associated with cancers in humans (Table 3). This biological effect may be initiated by the interaction between gliclazide and its target proteins. As previously described, the effect of gliclazide on cancer remains controversial. Piccinni and colleagues reported that use of gliclazide caused a series of adverse events in patients with bladder cancer [11]. Our KEGG pathway analysis also showed that gliclazide-related genes are associated with bladder cancer (Table 3). As such, we determined to explore the connectivity between gliclazide and bladder cancer. Additionally, the PI3K–Akt signal pathway, which is critical in the development of bladder cancer [18,19], is tightly linked to the gliclazide-associated network revealed by KEGG analysis (Table 3). This suggested that the use of gliclazide affects bladder cancer development through the PI3K–AKT pathway. Therefore, four overlapping genes (EGF, EGFR, VEGFA, and THBS1) were extracted from the bladder cancer and PI3K–AKT pathways. Notably, VEGFA is the primary target of gliclazide (Fig. 1). Next, we further explored the genomic alterations of gliclazide-associated genes in bladder cancer using cBioPortal. In bladder cancer patients, the majority of EGF and EGFR alterations are mRNA upregulation and amplification (Fig. 2), which led to an upregulation of their expression associated with the progression in bladder
Table 3. List of enriched gliclazide-related gene sets using WebGestalt. C, the number of genes referenced in a specific category; O, the number of genes that overlap both in gene set and category; E, expected number of genes within the category; R, the ratio of enrichment analysis; \( P \), calculated by the hypergeometric test.

| Pathway name                               | No. of genes | Gene (corresponding gene set)                                                                 | Statistics        |
|--------------------------------------------|--------------|-----------------------------------------------------------------------------------------------|-------------------|
| EGFR tyrosine kinase inhibitor resistance   | 15           | EGF, EGFR, ERBB2, AKT1, FGFR2, HGF, IGF1, IGF1R, KDR, MET, PDGFRB, PIK3CA, SRC, VEGFA, PDGFRB, R | C = 81; O = 15; E = 0.58; R = 26.06; P = 0 |
| Rap1 signaling pathway                     | 23           | RAPGEF3, RAPGEFA, EGFR, EGFR, AKT1, FGFR2, FLT1, FLT4, HGF, IGF1, IGF1R, KDR, MET, PDGFRB, PIK3CA, SRC, TEK, VEGA, VEGFA | C = 212; O = 23; E = 1.51; R = 15.26; P = 0 |
| HIF-1 signaling pathway                    | 17           | CREBBP, EGFR, EP300, ERBB2, AKT1, FLT1, HIF1A, HIF1R, ARNT, SERPINE1, PIK3CA, TEK, TIMP1, VEGFA, VHL | C = 103; O = 17; E = 0.73; R = 23.22; P = 0 |
| PI3K-Akt signaling pathway                 | 23           | CREBB1, EGFR, AKT1, FGFR2, FLT1, FLT4, HGF, HSP90AA1, IGF1, IGF1R, KDR, MET, PDGFRB, PIK3CA, SRC, TEK, THBS1, VEGFA, VEGFB, VWF | C = 341; O = 23; E = 2.42; R = 9.49; P = 0 |
| Focal adhesion                             | 22           | EGF, EGFR, ERBB2, AKT1, FLT1, FLT4, HGF, IGF1, IGF1R, JUN, KDR, RHOA, MET, PDGFRB, PIK3CA, SRC, TEK, THBS1, VEGFA, VEGFB, VWF | C = 203; O = 22; E = 1.44; R = 15.25; P = 0 |
| Pathways in cancer                         | 28           | CREBBP, EGFR, EP300, EP300, ERAF1, ERBB2, AKT1, FGFR2, HGF, HIF1A, HSP90AA1, IGF1, IGF1R, JUN, KDR, RHOA, ARNT, MET, MMP2, PIK3CA, PDGFRB, PDGFRB, TIMP1, VEGFA, VEGFB, VHL | C = 397; O = 28; E = 2.82; R = 9.92; P = 0 |
| Proteoglycans in cancer                    | 22           | EGFR, ERBB2, AKT1, FGFR2, GPC1, HGF, IGF1A, IGF1, IGF1R, JUN, KDR, RHOA, MET, PDGFRB, PIK3CA, PTK2, SRC, THBS1, VEGFA, VEGFB, VWF | C = 205; O = 22; E = 1.46; R = 15.10; P = 0 |
| Renal cell carcinoma                       | 14           | CREBBP, EGFR, EP300, EP300, ERAF1, AKT1, FGFR2, HGF, HIF1A, JUN, ARNT, MET, PDGFRB, PIK3CA, SRC, TEK, THBS1, VEGFA, VHL | C = 67; O = 14; E = 0.48; R = 29.40; P = 0 |
| Ras signaling pathway                      | 19           | EGFR, EGFR, AKT1, FGFR2, FLT1, FLT4, HGF, IGF1, IGF1R, KDR, KIT, MET, PDGFRB, PIK3CA, SRC, TEK, THBS1, VEGFA, VEGFB | C = 229; O = 19; E = 1.63; R = 11.67; P = 3.33E-16 |
| Prostate cancer                            | 13           | CREBB1, CREBBP, EGFR, EGFR, EP300, ERBB2, AKT1, HSP90AA1, IGF1, IGF1R, PDGFRB, PDGFRB, PIK3CA, TEK, TIMP3, VEGFA, VHL | C = 89; O = 13; E = 0.63; R = 20.55; P = 2.16E-14 |
| Melanoma                                   | 11           | EGFR, EGFR, AKT1, FGFR2, HGF, IGF1, IGF1R, JUN, KDR, MET, PDGFRB, PIK3CA, PTK2, SRC, THBS1, VEGFA, VHL | C = 71; O = 11; E = 0.50; R = 21.80; P = 1.39E-12 |
| Endocrine resistance                       | 11           | EGFR, ERBB2, AKT1, FGFR2, HGF, IGF1, IGF1R, JUN, MMP2, PIK3CA, PTK2, SRC, THBS1, VEGFA, VHL | C = 98; O = 11; E = 0.70; R = 15.79; P = 5.28E-11 |
| Bladder cancer                             | 8            | EGFR, EGFR, ERBB2, MMP2, MMP9, SRC, THBS1, VEGFA | C = 41; O = 8; E = 0.29; R = 27.45; P = 2.94E-10 |
| Cytokine-cytokine receptor interaction     | 14           | EGFR, EGFR, AKT1, FGFR2, HGF, IGF1, IGF1R, JUN, KDR, MET, PDGFRB, PDGFRB, PTK2, SRC, THBS1, VEGFA, VEGFB | C = 265; O = 14; E = 1.88; R = 7.43; P = 2.37E-09 |
| Breast cancer                              | 11           | EGFR, ERBB2, AKT1, FGFR2, FLT1, FLT4, HGF, IGF1, IGF1R, JUN, KIT, PIK3CA | C = 146; O = 11; E = 1.04; R = 10.60; P = 4.02E-09 |

cancer [30–32]. In terms of VEGFA, the most obvious change was amplification (Fig. 2), which promotes the expression of VEGFA in accordance with the development and poor prognosis in bladder cancer [33,34]. Furthermore, our results also revealed that patients with alterations in the four identified genes showed a lower overall survival rate (Fig. 4). This may offer a therapeutic insight into the use of gliclazide in T2DM with bladder cancer.

The use of gliclazide for site-specific types of cancer remains unclear. Some studies suggest that gliclazide can bring benefit to cancer patients because of its antioxidant effect [10]. However, other studies suggest that using gliclazide is not conducive to the treatment of cancers. Sliwinska and colleagues showed that the anti-oxidation effect of gliclazide does not merely protect normal cells against apoptosis, but also makes cancer cells resistant to apoptosis [35]. Meanwhile, gliclazide also has been reported to activate DNA repair in cancer cells rather than normal human cells [36]. Therefore, more reasonable and standardized clinical research and basic scientific research are needed to clarify the relationship between gliclazide and cancer. The biological network and pathway analysis we have constructed allows us to achieve this. The enriched KEGG pathway analysis also shows that gliclazide has the potential to affect renal and prostate cancer – an association which has not received enough attention.
Network study of gliclazide

W. Wen et al.

from researchers (Table 3). Thus, this approach can broaden our understanding of malignancy and help in early diagnosis and prognosis of disease. Also, mining and analyzing existing data based on open databases can not only provide relevant information such as drug safety, but also find a basis for drug repurposing and thereby reduce the cost of drug development.

Certain limitations within this analysis should be acknowledged. First, the validation of protein expression may better reveal the biological function of gliclazide, and this was actually not available in our study. The nature of the interactions needs further exploration to investigate the underlying mechanism by which gliclazide causes more side effects in bladder cancer patients. Second, other specific types of cancer pathways presented by enrichment analysis have not been explored. Whether the biological function network between gliclazide and bladder cancer displayed in this research can be extended to other cancers, such as renal and prostate cancer, remains for further exploration. However, the results of this research may provide the basis for further experimental work and help investigators translate basic study into clinical applications.

In conclusion, we integrated and used the open information databases to build a biological network to explore the relationship between gliclazide and cancer. As an increasing number of studies are conducted, more gliclazide-targeted proteins will be discovered in the future, which will help us better understand the mechanisms involved. We believe that this method can be conducted to guide basic research and clinical applications. For example, our study showed that genomic alterations of gliclazide-associated genes predict a poor prognosis for patients with bladder cancer. Therefore, for diabetes patients with cancer, especially bladder cancer, doctors should seriously consider whether they should choose hypoglycemic drugs with lower risks rather than gliclazide. Overall, this study provides a simple yet flexible approach to test the reasonable presumption of genetic alterations in bladder cancer and relevant information regarding drug safety by applying available drug information.

**Materials and methods**

**Drug-target search**

The DrugBank database is an available bioinformatics and cheminformatics tool able to query detailed drug data and provide comprehensive target information [37,38]. This database contains 11 033 drug entries, consisting of 2521 approved small molecules, 950 biotech drugs, 111 nutraceuticals, and over 5112 experimental drugs. The data are analyzed, grouped, and then used to establish a drug–target interactome. In this research, DrugBank was used to explore the indications and category for gliclazide. Additionally, the interaction between gliclazide and its targets was then generated for further construction of a gliclazide-associated biological network. These data were used to establish a visualization work following further analysis as well as to develop a proposal for future experiments.

**Network generation and pathway enrichment analysis**

STRING version 10.5 is a database of known and predicted protein–protein interactions, which includes direct (physical) and indirect (functional) associations [39]. The interaction information was generated from computational prediction and knowledge transfer between organisms as well as other (primary) databases. In this study, target proteins of gliclazide were obtained using the STRING online database, and the results were further visualized using Cytoscape (version 3.6.0) [40]. WebGestalt is an integrated functional enrichment analysis database that offers flexible and accurate analysis of functional enrichment pathways [41]. Gliclazide-associated genes were queried into the WebGestalt database, which resulted in the top 15 Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment pathways with P-values < 0.01.

**Cancer genomics data linked to gliclazide and bladder cancer survival analysis**

The cBioPortal is an open web-based database for exploring multidimensional cancer genomics information obtained from cancer samples [42,43]. Complicated genomic information is easily accessible enabling researchers to analyze their genetic alterations across cancer samples from various studies. The relevant information obtained is closely linked to the clinical outcomes, which is conducive to further exploring new connections. In this study, the cBioPortal database was used to analyze the connectivity of gliclazide-associated genes across bladder cancer studies, and these genes were taken as altered or unaltered in bladder cancer samples. Finally, the altered genes were used to perform a survival analysis using the cBioPortal database.

**Acknowledgements**

This work was supported by the National Natural Science Foundation of China (grant numbers 81670783, 81570716, 81770835 and 81774035); the Natural Science Foundation of Guangdong Province.
Conflict of interest

The authors declare no conflict of interest.

Author contributions

HC and JS conceived and designed the study; WW, JG and PW analyzed data and wrote the manuscript; MZ participated in data analysis; MW helped modify the manuscript and provided suggestions. All authors read and approved the final manuscript.

References

1 Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, Cavan D, Shaw JE and Makaroff LE (2017) IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 128, 40–50.

2 NCD Risk Factor Collaboration (NCD-RisC) (2016) Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 387, 1513–1530.

3 Shi Y and Hu FB (2014) The global implications of diabetes and cancer. Lancet 383, 1947–1948.

4 Singh AK and Singh R (2016) Is gliclazide a sulfonylurea with difference? A review in 2016. Expert Rev Clin Pharmacol 9, 839–851.

5 Al-Omary FAM (2017) Gliclazide. Profiles of Drug Subst Excip Relat Methodol. https://doi.org/10.1016/bs.podrm.2017.02.003

6 Hosker JP, Rudenski AS, Burnett MA, Matthews DR and Turner RC (1989) Similar reduction of first- and second-phase B-cell responses at three different glucose levels in type II diabetes and the effect of gliclazide therapy. Metabolism 38, 767–772.

7 Gribble FM and Reimann F (2003) Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions. J Diabetes Complications 17, 11–15.

8 Wrobel MP, Marek B, Kajdaniuk D, Rokicka D, Szymborska-Kajdanek A and Strojec K (2017) Metformin – a new old drug. Endokrynol Pol 68, 482–496.

9 Bowker SL, Majumdar SR, Veugelers P and Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29, 254–258.

10 Yang X, So WY, Ma RC, Yu LW, Ko GT, Kong AP, Ng VW, Luk AO, Ozaki R, Tong PC et al. (2010) Use of sulphonylurea and cancer in type 2 diabetes—The Hong Kong Diabetes Registry. Diabetes Res Clin Pract 90, 343–351.

11 Piccinni C, Motola D, Marchesini G and Poluzzi E (2011) Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 34, 1369–1371.

12 Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, Atreja A and Zimmerman RS (2012) Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis. Diabetes Obes Metab 14, 803–809.

13 Monami M, Balzi D, Lamanna C, Barchielli A, Masotti G, Buiatti E, Marchionni N and Mannucci E (2007) Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Rev 23, 479–484.

14 Chu SH, Liu YW, Zhang L, Liu B, Li L, Shi JZ and Li L (2013) Regulation of survival and chemoresistance by HSP90AA1 in ovarian cancer SKOV3 cells. Mol Biol Rep 40, 1–6.

15 Gibbs J, Cull W, Henderson W, Daley J, Hur K and Khuri SF (1999) Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the National VA Surgical Risk Study. Arch Surg 134, 36–42.

16 Saito H, Kono Y, Murakami Y, Shishido Y, Kuroda H, Matsunaga T, Fukumoto Y, Osaki T, Ashida K and Fujiwara Y (2018) Postoperative serum albumin is a potential prognostic factor for older patients with gastric cancer. Yonago Acta Med 61, 72–78.

17 The Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315–322.

18 Houede N and Pourquier P (2015) Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers. Pharmacol Ther 145, 1–18.

19 Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, Sakellariou S, Fragkou P, Isaiadis D, Pavlopoulos P et al. (2012) A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. BJU Int 110, E1237–E1248.

20 Claesson-Welsh L and Welsh M (2013) VEGFA and tumour angiogenesis. J Intern Med 273, 114–127.

21 Poyet C, Thomas L, Benoit TM, Delmo DA, Luberto L, Banzola I, Gunthart MS, Sais G, Eberli D, Sulser T et al. (2017) Implication of vascular endothelial growth

FEBS Open Bio 9 (2019) 457-467 © 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.

465
Network study of gliclazide

W. Wen et al.

factor A and C in revealing diagnostic lymphangiogenic markers in node-positive bladder cancer. Oncotarget 8, 21871–21883.

22 Zhong Z, Huang M, Lv M, He Y, Duan C, Zhang L and Chen J (2017) Circular RNA MYLK as a competing endogenous RNA promotes bladder cancer progression through modulating VEGFA/VEGFR2 signaling pathway. Cancer Lett 403, 305–317.

23 Kim PH, Cha EK, Sfakianos JP, Iyer G, Zabor EC, Scott SN, Ostrovnya I, Ramirez R, Sun A, Shah R et al. (2015) Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder. Eur Urol 67, 198–201.

24 Iyer G, Al-Ahmadie H, Schultz N, Hanrahan AJ, Ostrovnya I, Balar AV, Kim PH, Lin O, Weinhold N, Sander C et al. (2013) Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol 31, 3133–3140.

25 Al-Ahmadie HA, Iyer G, Lee BH, Scott SN, Mehra R, Bagrodia A, Jordan EJ, Gao SP, Ramirez R, Cha EK et al. (2016) Frequent somatic CDH1 loss-of-function mutations in placymoyt variant bladder cancer. Nat Genet 48, 356–358.

26 Guo G, Sun X, Chen C, Wu S, Huang P, Li Z, Dean M, Huang Y, Jia W, Zhou Q et al. (2013) Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet 45, 1459–1463.

27 Van Allen EM, Mouw KW, Kim P, Iyer G, Wagle N, Al-Ahmadie H, Zhu C, Ostrovnya I, Kryukov GV, O’Connor KW et al. (2014) Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 4, 1140–1153.

28 Wojciechowska J, Krajewski W, Bolanowski M, Kreciicki T and Zatonksi T (2016) Diabetes and cancer: a review of current knowledge. Exp Clin Endocrinol Diabetes 124, 263–275.

29 Bo S, Castiglione A, Ghigo E, Gentile L, Durazzo M, Cavallo-Perin P and Ciccone G (2013) Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients. Eur J Endocrinol 169, 117–126.

30 Imai T, Kimura M, Takeda M and Tomita Y (1995) Significance of epidermal growth factor receptor and c-erbB-2 protein expression in transitional cell cancer of the upper urinary tract for tumour recurrence at the urinary bladder. Br J Cancer 71, 69–72.

31 Popov Z, Gil-Diez-De-Medina S, Ravery V, Hoznek A, Bastuji-Garin S, Lefrere-Belda MA, Abbou CC and Chopin DK (2004) Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications. Urol Oncol 22, 93–101.

32 Lipponen P and Eskelinen M (1994) Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 69, 1120–1125.

33 Goddard JC, Sutton CD, Furness PN, O’Byrne KJ and Kockelbergh RC (2003) Microvessel density at presentation predicts subsequent muscle invasion in superficial bladder cancer. Clin Cancer Res 9, 2583–2586.

34 Bernardini S, Fauconnet S, Chabannes E, Henry PC, Adessi G and Bittard H (2001) Serum levels of vascular endothelial growth factor as a prognostic factor in bladder cancer. J Urol 166, 1275–1279.

35 Sliwinska A, Rogalska A, Szew M, Kasznicki J, Jozwiak Z and Drzewoski J (2012) Gliclazide may have an antiapoptotic effect related to its antioxidant properties in human normal and cancer cells. Mol Biol Rep 39, 5253–5267.

36 Sliwinska A, Sliwinski T, Kasznicki J and Drzewoski J (2010) Effect of gliclazide on nucleotide excision repair (NER) and non-homologous DNA end joining (NHEJ) in normal and cancer cells. J Physiol Pharmacol 61, 347–353.

37 Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z et al. (2018) DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res 46, D1074–D1082.

38 Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z and Woolsey J (2006) DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 34, D668–D672.

39 Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P et al. (2017) The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res 45, D362–D368.

40 Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13, 2498–2504.

41 Wang J, Vasaikar S, Shi Z, Greer M and Zhang B (2017) WebGestalt 2017: a more comprehensive, powerful, flexible and interactive gene set enrichment analysis toolkit. Nucleic Acids Res 45, W130–W137.

42 Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E et al. (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6, pl1.
43 Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E et al. (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2, 401–404.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. Fifty gliclazide-related genes.